Filing Details
- Accession Number:
- 0000950170-23-058943
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-03 18:49:33
- Reporting Period:
- 2023-11-01
- Accepted Time:
- 2023-11-03 18:49:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1088856 | Corcept Therapeutics Inc | CORT | Pharmaceutical Preparations (2834) | 770487658 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1817838 | Douglas Joseph Lyon | C/O Corcept Therapeutics Incorporated 149 Commonwealth Drive Menlo Park CA 94025 | Chief Accounting Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-11-01 | 1,023 | $11.35 | 6,877 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-11-01 | 1,023 | $28.08 | 5,854 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-11-02 | 3,977 | $11.35 | 9,831 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-11-02 | 3,977 | $28.11 | 5,854 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (right to buy) | Disposition | 2023-11-01 | 1,023 | $0.00 | 1,023 | $11.35 |
| Common Stock | Stock option (right to buy) | Disposition | 2023-11-02 | 3,977 | $0.00 | 3,977 | $11.35 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 53,144 | 2029-02-08 | No | 4 | M | Direct | |
| 49,167 | 2029-02-08 | No | 4 | M | Direct |
Footnotes
- Includes 1,155 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,411 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023 and 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
- Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $28.08 to $28.1244. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- Fully exercisable.
Billionaire Hedge Funds
